Drugs Against Covid-19

Review

. 2020 Apr 29;157:104859.

 doi: 10.1016/j.phrs.2020.104859. Online ahead of print.

Candidate Drugs Against SARS-CoV-2 and COVID-19

Dwight L McKee 1, Ariane Sternberg 2, Ulrike Stange 2, Stefan Laufer 3, Cord Naujokat 4

Affiliations 

• PMID: 32360480
 
• PMCID: PMC7189851
 
• DOI: 10.1016/j.phrs.2020.104859

Abstract

Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.

Keywords: Arbidol; COVID-19; Camostat; Chloroquine; Drugs; Favipiravir; Lopinavir; Phytochemicals; Remdesivir; Ritonavir; SARS-CoV-2.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Conflict of interest statement

Declaration of Competing Interest None.

Figures

 

Fig. 1 

5

Structural formulas of candidate drugs...

Similar articles

• A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19).
  

  Mali SN, Thorat BR, Chopade AR.Infect Disord Drug Targets. 2020 May 10. doi: 10.2174/1871526520666200511005546. Online ahead of print.PMID: 32389117
• A global treatments for coronaviruses including COVID-19.
  

  Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M.J Cell Physiol. 2020 May 11. doi: 10.1002/jcp.29785. Online ahead of print.PMID: 32394467 Review.
• Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.
• Magrone T, Magrone M, Jirillo E.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print.PMID: 32338224
• Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19.
  

  Huang J, Song W, Huang H, Sun Q.J Clin Med. 2020 Apr 15;9(4):E1131. doi: 10.3390/jcm9041131.PMID: 32326602 Review.

 See all similar articles

References

1. 1. Lu R., Zhao X., Li J., Niu P., Wang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. - PMC - PubMed
2. 1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med. 2019;383(8):727–733. 2020.
3. 1. https://coronavirus.jhu.edu/map.html Johns Hopkins University, USA, (2020).
4. 1. Li C., Yang Y., Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infect. Genet. Evol. 2020;82
5. 1. Anthony S.J., Johnson C.K., Greig D.J., Kramer S., Che X., Wells H. Global patterns in coronavirus diversity. Virus Evol. 2017;3(1):vex012. - PMC - PubMed

 

Publication types

• 
  

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Miscellaneous

  • NCI CPTAC Assay Portal